Stock EQRX EQRX, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News EQRx, Inc.

Equities

EQRX

US26886C1071

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revolution Medicines Closes Acquisition of EQRx in All-Stock Deal
MT
EQRx, Inc. Announces Board Resignations
CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index
CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index
CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Biotechnology Select Industry Index
CI
EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P TMI Index
CI
Revolution Medicines, Inc. completed the acquisition of EQRx, Inc. from a group of shareholders.
CI
Revolution Medicines, EQRx Stockholders Approve Merger
MT
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
AQ
EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Biotechnology Index
CI
EQRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Calling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
PR
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
BU
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders
BU
EQRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Hansoh Pharmaceutical Terminates License Agreement With EQRx for Aumolertinib; Shares Slump 10%
MT
EQRx : Termination of Material Agreement - Form 8-K
PU
EQRx, Inc. Provides Written Notice to G1 Therapeutics of its Termination of the Exclusive License Agreement
CI
EQRx, Inc. Provides Written Notice to Hansoh Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Ltd. of Its Termination of the Strategic Collaboration License Agreement
CI
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EQRX Stock
  4. News EQRx, Inc.